IVD Cancer Diagnostic Products to be Based on Microarrays

Microarray-based tests will enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.

Affymetrix, Inc. (Santa Clara, CA, USA) and Ipsogen have signed a Powered by Affymetrix (PbA) agreement, which gives Ipsogen (Marseilles, France) non-exclusive access to Affymetrix microarray technology to develop and market in vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis. The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products.

Ipsogen is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. "Ipsogen's strong expertise in delivering high medical value IVD products in the field of blood cancers will be leveraged together with our new PbA capabilities to expedite the launch of a range of innovative and unique IVD tests for guiding breast cancer therapies,” said Vincent Fert, president and CEO of Ipsogen.

"The microarray-based tools and applications in the Powered by Affymetrix program continue to accelerate the discovery and development of oncology diagnostics products,” said Noel Doheny, senior vice president, Molecular Diagnostics at Affymetrix. "This is the era of personalized medicine and we are pleased that another innovator in the molecular diagnostic field like Ipsogen has adopted our proven technology platform.”


Related Links:
Affymetrix
Ipsogen